Exondys 51™ (eteplirsen) – New orphan drug approval
September 19, 2016 – The FDA announced the approval of Sarepta Therapeutics’ Exondys 51 (eteplirsen) for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
Top